Current Report Filing (8-k)
December 08 2016 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 8, 2016
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State
or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
|
6800
Broken Sound Parkway NW, Third Floor
Boca
Raton, FL 33487
|
|
|
(Address
of Principal Executive Office) (Zip Code)
|
|
Registrant's
telephone number, including area code: (561) 961-1900
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2 below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
TherapeuticsMD, Inc. is
furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or in part,
and subject to modification, on December 8, 2016 and at subsequent meetings with investors or analysts.
The information in this
Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed
to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth
by specific reference in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
TherapeuticsMD, Inc. presentation dated December 2016.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: December 8, 2016
|
THERAPEUTICSMD, INC.
|
|
|
|
By:
|
/s/
Daniel A. Cartwright
|
|
Name:
|
Daniel A. Cartwright
|
|
Title:
|
Chief Financial Officer
|
EXHIBIT INDEX
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024